These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38862340)

  • 1. Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Sutera P; Song Y; Shetty AC; English K; Van der Eecken K; Guler OC; Wang J; Cao Y; Bazyar S; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Kiess A; Song DY; DeWeese T; Pienta KJ; Barbieri C; Marchionni L; Ren L; Sawant A; Simone N; Berlin A; Onal C; Tran PT; Ost P; Deek MP
    Eur Urol Oncol; 2024 Jun; ():. PubMed ID: 38862340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.
    Sutera P; Deek MP; Van der Eecken K; Shetty AC; Chang JH; Hodges T; Song Y; Verbeke S; Van Dorpe J; Fonteyne V; De Laere B; Mishra M; Rana Z; Molitoris J; Ferris M; Ross A; Schaeffer E; Roberts N; Song DY; DeWeese T; Pienta KJ; Antonarakis ES; Ost P; Tran PT
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1095-1101. PubMed ID: 36708787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
    Sutera P; Song Y; Van der Eecken K; Shetty AC; English K; Hodges T; Chang J; Fonteyne V; Rana Z; Ren L; Mendes AA; Lumen N; Delrue L; Verbeke S; De Man K; Song DY; Pienta K; Feng FY; Joniau S; Lotan T; Lane B; Kiess A; Rowe S; Pomper M; DeWeese T; Deek M; Sweeney C; Ost P; Tran PT
    Eur Urol; 2023 Dec; 84(6):531-535. PubMed ID: 37173210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
    Deek MP; Van der Eecken K; Phillips R; Parikh NR; Isaacsson Velho P; Lotan TL; Kishan AU; Maurer T; ; Boutros PC; Hovens C; Abramowtiz M; Pollack A; Desai N; Stish B; Feng FY; Eisenberger M; Carducci M; Pienta KJ; Markowski M; Paller CJ; Antonarakis ES; Berlin A; Ost P; Tran PT
    Eur Urol; 2021 Nov; 80(5):632-640. PubMed ID: 33419682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-based Mutational Profiles Predict Visceral Metastasis Outcome and Early Death in Prostate Cancer Patients.
    Cussenot O; Timms KM; Perrot E; Blanchet P; Brureau L; Solimeno C; Fromont G; Comperat E; Cancel-Tassin G
    Eur Urol Oncol; 2024 Jun; 7(3):597-604. PubMed ID: 38182487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
    Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Lopez Campos F; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
    Eur Urol Oncol; 2024 Dec; 7(6):1403-1410. PubMed ID: 38570239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and genomic features of SPOP-mutant prostate cancer.
    Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
    Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
    Deek MP; Taparra K; Dao D; Chan L; Phillips R; Gao RW; Kwon ED; Deville C; Song DY; Greco S; Carducci MA; Eisenberger M; DeWeese TL; Denmeade S; Pienta K; Paller CJ; Antonarakis ES; Olivier KR; Park SS; Stish BJ; Tran PT
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):387-395. PubMed ID: 32798608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
    Stangl A; Wilner C; Li P; Maahs L; Hwang C; Pilling A
    Prostate; 2023 May; 83(6):524-533. PubMed ID: 36604824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
    Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.
    Sutera P; Shetty AC; Song Y; Hodges T; Hoang T; Rana Z; Pienta K; Feng F; Song DY; DeWeese T; Gillessen S; Sweeney C; James N; Attard G; Deek M; Tran PT
    Eur Urol Oncol; 2024 Apr; 7(2):241-247. PubMed ID: 37558543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.
    Hoang T; Sutera P; Nguyen T; Chang J; Jagtap S; Song Y; Shetty AC; Chowdhury DD; Chan A; Carrieri FA; Hathout L; Ennis R; Jabbour SK; Parikh R; Molitoris J; Song DY; DeWeese T; Marchionni L; Ren L; Sawant A; Simone N; Lafargue A; Van Der Eecken K; Bunz F; Ost P; Tran PT; Deek MP
    Prostate; 2024 Jan; 84(1):87-99. PubMed ID: 37812042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
    Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
    Friedes C; Yegya-Raman N; Zhang S; Iocolano M; Cohen RB; Aggarwal C; Thompson JC; Marmarelis ME; Levin WP; Cengel KA; Ciunci CA; Singh AP; D'Avella C; Davis CW; Langer CJ; Feigenberg SJ
    Clin Lung Cancer; 2024 Jan; 25(1):50-60.e6. PubMed ID: 37813713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
    Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
    Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.
    Deek MP; Van der Eecken K; Sutera P; Deek RA; Fonteyne V; Mendes AA; Decaestecker K; Kiess AP; Lumen N; Phillips R; De Bruycker A; Mishra M; Rana Z; Molitoris J; Lambert B; Delrue L; Wang H; Lowe K; Verbeke S; Van Dorpe J; Bultijnck R; Villeirs G; De Man K; Ameye F; Song DY; DeWeese T; Paller CJ; Feng FY; Wyatt A; Pienta KJ; Diehn M; Bentzen SM; Joniau S; Vanhaverbeke F; De Meerleer G; Antonarakis ES; Lotan TL; Berlin A; Siva S; Ost P; Tran PT
    J Clin Oncol; 2022 Oct; 40(29):3377-3382. PubMed ID: 36001857
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of widespread metastases and of metastatic tropism in patients with prostate cancer: A genomic analysis of primary and metastatic tumors.
    Alshalalfa M; Goglia AG; Swami N; Nguyen B; Hougen HY; Khan A; Kishan AU; Punnen S; Nguyen PL; Mahal BA; Dee EC
    Urol Oncol; 2023 May; 41(5):253.e21-253.e26. PubMed ID: 37003878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer.
    Broderick A; Pan E; Li J; Chu A; Hwang C; Barata PC; Cackowski FC; Labriola M; Ghose A; Bilen MA; Kilari D; Thapa B; Piero M; Graham L; Tripathi A; Garje R; Koshkin VS; Hernandez E; Dorff TB; Schweizer MT; Alva AS; McKay RR; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2024 Jul; ():. PubMed ID: 39019980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
    Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.